Gilead Sciences and Lakefront Biotherapeutics have acquired Ouro Medicines and its investigational therapy, gamgertamig, for cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA). Gamgertamig is also being developed as a treatment for several other autoimmune diseases. Under the deal, valued at up to $2.175 billion,…
News
A 70-year-old woman with cold agglutinin disease (CAD) avoided disease-related complications from surgery related to a heart condition, in part because she took Enjaymo (sutimlimab-jome) before the operation for a heart condition, a case study from the U.S. reported. In addition to giving the woman Enjaymo, an approved…
A woman with cold agglutinin disease (CAD) who was misdiagnosed with and treated for a blood cancer achieved lasting health improvements once doctors switched her to Enjaymo (sutimlimab-jome), a case study shows. The woman had initially received therapies for chronic lymphocytic leukemia (CLL). However, those treatments failed to…
A 78-year-old woman with cold agglutinin disease (CAD) was later found to have acute myeloid leukemia (AML), a type of blood cancer, which likely caused the disease, according to a case study from the U.S. Doctors discovered the woman’s AML after her anemia continued to worsen despite signs that…
Cold agglutinin disease (CAD) rarely occurs without abnormal immune cell growth in the bone marrow or blood, but this abnormal cell growth is often hard to detect with standard assessments, a new study shows. “Our data underscore the importance of a comprehensive and sensitive approach when evaluating bone marrow…
Enjaymo (sutimlimab-jome) rapidly and sustainably reduces red blood cell destruction and the need for blood transfusions in most adults with hard-to-treat cold agglutinin disease (CAD) in real-world clinical settings, a study showed. “[Enjaymo] demonstrated rapid, durable effectiveness and a favorable safety profile in heavily pretreated real-world CAD patients,”…
Primary cold agglutinin disease (CAD) is not a single, uniform disease and can be difficult to distinguish from certain blood cancers, making it challenging to diagnose using standard criteria, a study in Japan suggests. Researchers found that, even after excluding cases linked to underlying conditions — known as cold…
A single dose of the cell therapy candidate zorpocabtagene-autoleucel (zorpo-cel) led to rapid, durable symptom relief in a woman with severe, hard-to-treat cold agglutinin disease (CAD) in a rare combination with two other autoimmune disorders, a case study reported. The woman had been dependent on blood transfusions for…
A woman in her 50s battling advanced breast cancer developed a rare blood disorder called cold agglutinin disease (CAD) as a direct complication of her chemotherapy treatment. According to a recent case study, the woman’s immune system began attacking her own red blood cells after she received paclitaxel. While…
A woman in her 50s developed cold agglutinin disease (CAD) and kidney injury as rare complications of a bacterial lung infection caused by Mycoplasma pneumoniae (M. pneumoniae), according to a case report. Although these infections can trigger the production of cold agglutinins, the self-reactive antibodies that cause CAD, in up…
Recent Posts
- Potential therapy for rare blood disorders acquired by companies
- Issues pile up when I neglect the management of both CAD and my yard
- Enjaymo, warmth protect CAD patient during surgery: Case report
- After 50 years, my husband and I have ‘only just begun’
- Why I said no to yet another CAD blood test
- Enjaymo brings lasting gains for CAD patient misdiagnosed with cancer
- Myeloid leukemia turns up as hidden cause of CAD: Case study
- The life lessons I learned from frigid Friday night football games
- CAD study highlights need for more sensitive bone marrow testing
- Five things I do to have a positive patient experience